Drugs / DSP-7888 Dosing Emulsion
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03311334 | Dec 2017 → Oct 2022 | fallopian tube cancer, ovarian serous adenocarcinoma, primary peritoneal carcinoma, renal cell carcinoma +1 | Sumitomo Pharma America, Inc. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DSP-7888 Dosing Emulsion | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03311334 ↗ |
| Route | Other | “DSP-7888 Dosing Emulsion will be administered intradermally (ID)” NCT03311334 ↗ |